United States v. Otuonye

995 F.3d 1191
Court of Appeals for the Tenth Circuit·Decided May 4, 2021·No. 19-3250·Published·Cited by 22 cases

Opinion

FILED

United States Court of Appeals PUBLISH Tenth Circuit

UNITED STATES COURT OF APPEALS May 4, 2021

Christopher M. Wolpert

FOR THE TENTH CIRCUIT Clerk of Court

UNITED STATES OF AMERICA, Plaintiff - Appellee, v. No. 19-3250 EBUBE OTUONYE,

Defendant - Appellant.

Appeal from the United States District Court for the District of Kansas (D.C. No. 6:18-CR-10085-EFM-1)

Michael D. Kimerer, Kimerer Law Group, P.C., Phoenix, Arizona, for Defendant – Appellant.

James A. Brown, Assistant United States Attorney (Stephen R. McAllister, United States Attorney with him on the brief), Topeka, Kansas, for Plaintiff – Appellee.

Before MATHESON, BALDOCK, and MORITZ, Circuit Judges.

MATHESON, Circuit Judge.

Wichita pharmacist Ebube Otuonye filled prescriptions written by Dr. Steven Henson for opioids and other controlled substances. The Drug Enforcement Administration (“DEA”) became suspicious of Dr. Henson’s prescriptions and investigated him, which led them to Mr. Otuonye.

Based on the results of the DEA’s investigation, Mr. Otuonye was indicted for conspiring to unlawfully distribute controlled substances under 21 U.S.C. § 846 (Count 1); unlawfully distributing controlled substances under 21 U.S.C. § 841(a)(1), (b)(1)(C), and 18 U.S.C. § 2 (Count 2); and Medicare and Medicaid fraud in violation of 18 U.S.C. § 1347 (Counts 3 and 4). A jury convicted Mr. Otuonye on all four counts. The district court imposed a 150-month concurrent prison sentence.

Mr. Otuonye raises seven issues on appeal. Five challenge the admission of evidence. The sixth challenges the sufficiency of the evidence for all four convictions. Finally, Mr. Otuonye argues the district court committed procedural error by miscalculating his sentencing guidelines range.

Exercising jurisdiction under 28 U.S.C. § 1291 and 18 U.S.C. § 3742(a), we affirm.

I. BACKGROUND

A. Legal Background

The Controlled Substances Act (“CSA”), 21 U.S.C. §§ 801-904, classifies controlled substances into five drug schedules based on their medical use and potential for abuse. Oxycodone, methadone, and hydromorphone, which have accepted medical uses but are highly addictive, are classified as Schedule II drugs. 21 C.F.R. § 1308.12(b)(1), (c). Alprazolam, a central nervous system depressant used to treat insomnia and anxiety, is classified as a Schedule IV drug. 21 C.F.R. § 1308.14(c)(2).

Title 21 U.S.C. § 841(a)(1) makes it unlawful, except under circumstances authorized by the statute, “for any person knowingly or intentionally . . . to manufacture,

distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance.” But 21 U.S.C. § 829 provides an exception allowing licensed, registered, or permitted practitioners to prescribe controlled substances in four of the five schedules, including Schedule II and Schedule IV. See 21 U.S.C. § 802(21) (defining a “practitioner” who may prescribe controlled substances).

DEA regulations implementing 21 U.S.C. § 829 specify:

A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription.

21 C.F.R. § 1306.4(a) (emphasis added). Thus, a pharmacist violates the CSA by distributing controlled substances in a manner inconsistent with the usual course of contemporary medical practice. See United States v. Lovern, 590 F.3d 1095, 1101 (10th Cir. 2009).

B. Factual Background

DEA Investigation In October 2014, the DEA began receiving phone calls from Wichita-area pharmacists raising concerns about the prescribing patterns of Dr. Henson—particularly his prescribing high doses of opioids and combining opioids with benzodiazepines such as Xanax (alprazolam). DEA Task Force Officer (“TFO”) Mikeal Long testified at trial that, in addition to the types and doses of drugs being prescribed, the fact that “[p]atients were coming from all over to see Dr. Henson” raised suspicion. Jt. App., Vol. 7 at 1550.

The DEA also observed several other red flags. For example, Dr. Henson’s patients often paid in cash. And once a pharmacy filled one prescription written by Dr. Henson, many of his patients would come later that day or the following day to have their prescriptions filled, suggesting coordination among patients.

a. Neighborhood Pharmacy Through surveillance of Dr. Henson, the DEA identified a group of individuals who would drive from Kansas City, Lawrence, or Topeka to Wichita to buy prescriptions from Dr. Henson, have them filled at pharmacies, and sell the pills on the street.1 The DEA confronted Amanda Terwilleger, a member of that group. Ms.

Terwilleger told investigators that some pharmacists refused to fill Dr. Henson’s prescriptions, so she took her prescriptions to Neighborhood Pharmacy in Wichita. But Neighborhood had a policy requiring customers to fill three non-controlled prescriptions for every controlled prescription. Ms. Terwilleger did not have any non-controlled prescriptions.

Neighborhood Pharmacy was a retail pharmacy owned and operated by Mr.

Otuonye, its pharmacist-in-charge. It was licensed by the Kansas Board of Pharmacy and the DEA to distribute controlled substances.

1 The DEA also later identified a second such group from the Newton, Kansas area, spearheaded by Nick McGovern, a Dr. Henson patient. Mr. McGovern reportedly recruited others to go to Dr. Henson to get prescriptions. He would retain a portion of the drugs. Associates of Mr. McGovern testified at trial.

The DEA interviewed several other patients of Dr. Henson who reported they had difficulty filling Dr. Henson’s prescriptions at other pharmacies but were able to fill them at Neighborhood Pharmacy. The investigation revealed that, beginning in October 2014, an increasing number of Dr. Henson’s patients had prescriptions filled at Neighborhood.2 Dr. Henson’s patients often traveled long distances to have their prescriptions filled at Neighborhood. At trial, TFO Kyle Twaddle presented a series of maps showing the distances between the homes of Dr. Henson’s patients and Neighborhood Pharmacy. Most were outside a 2-mile radius from Neighborhood.3 Carly Haynes, the Kansas Board of Pharmacy’s Director of Compliance, had earlier testified that this was a red flag because “most patients will fill either at a pharmacy close to home or a pharmacy close to the physician.” Jt. App., Vol. 10 at 2207.

b. Evidence seized from Dr. Henson’s home Based on its investigation, the DEA obtained and executed a search warrant at Dr.

Henson’s home in August 2015. At that time, Dr. Henson voluntarily surrendered his DEA registration number, so he could no longer prescribe controlled substances. The search uncovered a series of handwritten notecards appearing to reference Mr. Otuonye or Neighborhood Pharmacy. One dated October 11, 2014, said “NEIGHBORHOOD

2 Only two patients had prescriptions for controlled substances written by Dr.

Henson filled at Neighborhood before October 2014—one on August 28, 2014, and one on September 30, 2014.

3 TFO Twaddle testified that the 2-mile radius was arbitrarily determined to help visualize these distances.

PHARMACY - 20%”; and another dated October 27, 2014, said “NEIGHBORHOOD PHARMACY/CAN THEY HANDLE.” Jt. App., Vol. 12A at 2552-53 (Gov’t Exhs. 4, 5).

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Otuonye, 995 F.3d 1191 (10th Cir. 2021).

995 F.3d 1191 (United States v. Otuonye) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Back
Tenth Circuit, 2026
United States v. Otuonye
Tenth Circuit, 2026
United States v. Tonya Robinson
Seventh Circuit, 2025
United States v. Albert Smith
Seventh Circuit, 2025
United States v. Butler (G'Ante)
141 F.4th 1136 (Tenth Circuit, 2025)
United States v. Rivera
Tenth Circuit, 2025
United States v. Taylor
Tenth Circuit, 2025
United States v. Pritchett
Tenth Circuit, 2025
Tyler v. United States
W.D. Oklahoma, 2025
Coleman v. Smith
D. Maryland, 2024
United States v. Moss
Tenth Circuit, 2024
United States v. McFadden
116 F.4th 1069 (Tenth Circuit, 2024)
Varnell v. United States
W.D. Oklahoma, 2024
United States v. Veneno
94 F.4th 1196 (Tenth Circuit, 2024)
United States v. Ferguson
Tenth Circuit, 2022
Cano v. Williams
Tenth Circuit, 2022